Bhardwaj Boddapati Kalyani, Thankachan Sanu, Venkatesh Thejaswini, Suresh Padmanaban S
School of Biotechnology, National Institute of Technology, Calicut 673601, Kerala, India.
Dept of Biochemistry and Molecular Biology, Central University of Kerala, Kasargod 671316, Kerala, India.
Clin Chim Acta. 2020 Nov;510:28-34. doi: 10.1016/j.cca.2020.06.047. Epub 2020 Jul 3.
Ovarian cancer is typically diagnosed at an advanced stage and poses a significant challenge to treatment and recovery. Relapsed ovarian cancer and chemoresistance of ovarian tumor cells are other clinical challenges. Liquid biopsy is an essential non-invasive diagnostic test that evaluates circulating tumor cells and tumor DNA, as well as other blood markers that may be useful in guiding precision medicine. Although liquid biopsy is not a routinely used diagnostic test, the potential applications in the diagnosis and prognosis in ovarian cancer are rapidly growing. This review explores recent studies examining the clinical potential of circulating tumor cells, cell-free microRNA, exosomes, tumor DNA, and other analytes as a source of liquid biopsy biomarkers in ovarian cancer diagnosis, prognosis and response to treatment.
卵巢癌通常在晚期被诊断出来，这对治疗和康复构成了重大挑战。复发性卵巢癌和卵巢肿瘤细胞的化疗耐药性是其他临床挑战。液体活检是一种重要的非侵入性诊断测试，可评估循环肿瘤细胞和肿瘤DNA，以及其他可能有助于指导精准医学的血液标志物。尽管液体活检并非常规使用的诊断测试，但其在卵巢癌诊断和预后方面的潜在应用正在迅速增加。这篇综述探讨了最近的研究，这些研究考察了循环肿瘤细胞、游离微小RNA、外泌体、肿瘤DNA和其他分析物作为液体活检生物标志物来源在卵巢癌诊断、预后和治疗反应中的临床潜力。
